title: New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
abstract: Recent advances in Hodgkin lymphoma research are expected to prelude a promising new treatment era for patients and their treating physicians. Scientific investigations over the last few years have provided new insights into risk stratification, and, simultaneously, a plethora of novel targeted therapies are emerging for patients with relapsed and refractory disease. These novel therapies will be tested primarily in high-risk patients because 75% of the patients are cured with conventional therapies. The challenges, as Hodgkin lymphoma therapy moves forward, will be using these biologic insights to identify the patients who may benefit earlier in treatment from these novel agents, and tailoring the therapy to the tumor biology of the patient. These dual aims are intertwined; as our therapeutic arsenal increases, these biologic determinants of risk may themselves inform the design of therapies and the choice of treatments for high-risk patients.
authors: Department of Medicine, New York University School of Medicine, NYU Cancer Institute, New York, New York 10016, USA. catherine.diefenbach@nyumc.org
authors: Catherine
authors: C
authors: Diefenbach
authors: Christian
authors: C
authors: Steidl
mesh_terms: D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D058990:Molecular Targeted Therapy; D011379:Prognosis